Shorter Infusion Time Approved for Teflaro Antibacterial

Allergan's ceftaroline fosamil is now approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia with a shorter infusion time.

Allergan’s ceftaroline fosamil (Teflaro) is now approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) with a shorter infusion time.

Teflaro’s label has been updated to reflect that it can now be administered by intravenous (IV) infusion in 5 minutes to 1 hour in adult patients with CABP and ABSSSI, including those with baseline Staphylococcus aureus bacteremia.

Recommended dosing is 600 mg in a 5- to 60-minute IV infusion every 12 hours for 5 to 14 days for ABSSSI, and for 5 to 7 days for CABP.

“With a shorter infusion time, Teflaro provides increased flexibility in dosing that may allow physicians, nurses, and other health care professionals to optimize the delivery of care in hospital and home settings,” stated David Nicholson, executive vice president and president of Global Brands Research and Development at Allergan.

Patients with renal impairment should receive Teflaro in a 5- to 60-minute IV infusion every 12 hours at the following dosages based on creatinine clearance:

· >50 CrCl (mL/min): 600 mg '

· >30 to <50 CrCl (mL/min): 400 mg '

· >15 to <30 CrCl (mL/min): 300 mg '

· End-stage renal disease (CrCl <15 mL/min), including hemodialysis: 200 mg